Background: Identifying immunologic mechanisms that contribute to premature cardiovascular disease (CVD) among HIV-positive patients will inform prevention strategies.
Introduction
HIV-positive persons are at increased risk for premature atherosclerotic cardiovascular disease (CVD), which is now a leading cause of morbidity and mortality among contemporary patients with access to effective combination antiretroviral therapy (ART) [1, 2] . Pro-atherogenic factors among HIV-positive patients include a greater prevalence of traditional risk factors (e.g., smoking), consequences of HIV replication, and exposure to certain antiretroviral medications [3] [4] [5] . We have shown that both HIV replication and exposure to protease inhibitors are associated with greater progression of subclinical atherosclerotic disease among participants in the SUN study (Study to Understand the Natural History of HIV/AIDS in the Era of Effective Therapy) [6] .
Recent data suggest that chronic inflammation may partly account the excess CVD risk attributable to HIV infection [7, 8] . However, few data exist on the immunologic mechanisms underlying inflammation-CVD risk associations among HIV-positive patients. Cardiac computed tomography (CT) estimates of coronary artery calcified plaque (coronary artery calcium, CAC) provide a noninvasive assessment of subclinical atherosclerosis that also correlates with the extent of histologically confirmed noncalcified plaque [9, 10] . In addition, CAC progression is independently associated with future risk for atherosclerotic CVD events and all-cause mortality, and adding CAC assessments to traditional risk factor prediction significantly improves risk classification for coronary heart disease (CHD) or stroke [11] [12] [13] [14] .
We conducted a longitudinal analysis of participants in the SUN study, and hypothesized that pro-inflammatory cellular phenotypes would predict CAC progression independent of traditional and HIV infection-related clinical factors. The most widely studied measure of immune activation in HIV-positive persons is the frequency of CD4 þ or CD8 þ T-cell expressing activation markers (e.g., CD38/HLA-DR), which independently predicts risk for AIDS progression and has more recently been associated with subclinical CVD [15, 16] . Abnormalities in innate, or nonspecific, immunity have also been described among HIV-positive patients, such as a higher prevalence of circulating monocytes that express CD16 þ cell [17, 18] . Three distinct monocyte subpopulations have been defined, based on expression of CD14 and CD16: classical (CD14 þ /CD16 À ), intermediate (CD14 þ /CD16 þ ), and nonclassical (CD14 dim /CD16 þ ) phenotypes [19] . Intermediate and nonclassical monocyte phenotypes may reflect a more activated immunologic state, demonstrating greater release of pro-inflammatory cytokines and an affinity for attaching to vascular surfaces, respectively [20] [21] [22] [23] . These data, along with the well accepted role of monocytes in CVD pathogenesis [24] , motivated our decision to study monocytes subpopulations along with more traditional T-cell phenotypes associated with HIV disease risk.
Methods

Study design
The SUN study is a Centers for Disease Control and Prevention (CDC)-funded prospective observational cohort study of HIV-infected participants enrolled at seven clinics in four US cities (Denver, Minneapolis, Providence, and St Louis) between March 2004 and June 2006 [25] . The protocol was approved by ethics committees at the CDC and each clinical site. Participants provided written informed consent. The SUN study design and cohort have been previously described [25] . Participant visits occurred at baseline and every 6 months thereafter, with a CAC measurement obtained at the baseline and year 2 visit. Participants enrolled in the SUN study were either naive to ART or their prior antiretroviral exposure had consisted solely of combination ART [!three nucleoside reverse transcriptase inhibitors (NRTIs) or ! three antiretroviral drugs from at least two different classes], and were expected to survive at least 2 years. Participants were included in this analysis if they had CAC measurements at both the baseline and 2-year visit.
Clinical data, including all medications and diagnoses, were abstracted and entered into a database (Clinical Practice Analyst; Cerner Corporation, Vienna, Virginia, USA), with additional data provided by a study-specific physical examination, laboratory testing, and an audio computer-assisted self-interview (ACASI). The presence of hypertension was defined as a blood pressure (BP) more than 140/90 mmHg, prescription of antihypertensives, or a diagnosis of hypertension. We estimated glomerular filtration rate (GFR) using the Cockcroft-Gault equation and Framingham 10-year CHD risk score (FRS) using published score sheets [26] .
Laboratory measurements
Following each visit, fasting whole blood and plasma specimens were shipped overnight to the CDC. Peripheral blood mononuclear cells (PBMCs) were isolated and cryopreserved in liquid nitrogen centrally at a CDC laboratory within 30 h of blood draw. Clinical site laboratory testing included measurement of fasting serum lipids, plasma HIV RNA viral load, and CD4 þ T-cell counts.
Immunophenotyping was performed on cryopreserved PBMCs using multicolor flow cytometry. Panels of fluorochrome-conjugated antibodies for cell surface markers not affected by cryopreservation (and viability dye to exclude nonviable cells) have been validated [27] . The fluorochrome-conjugated antibodies used to characterize cellular phenotypes were as follows: anti-CD38 PE-Cy7(Clone:HIT2), anti-CX3CR1 PE(Clone: 2A9-1), anti-CD28 PE-Cy7(Clone:CD28.2), anti-CD4 efluor605(Clone:OKT4), and anti-HLADR efluor605 (Clone:LN3) from eBioscience (San Diego, California, USA), anti-CD57 APC(Clone:HCD57), anti-CD27 Ax700(Clone:O323), anti-CX3CR1 APC(Clone:2A9-1), anti-CD16 PE-Cy7(Clone:3G8), and anti-CCR2 PerCp-Cy5.5(Clone:TG5) from BioLegend (San Diego, California, USA), anti-HLADR PE(Clone:G46-6), anti-CD3 APC-Cy7(Clone:SK7), anti-CD8 PB(Clone: RPA-T8), anti-CD14 PE(Clone:M5E2), anti-CCR5 APC-Cy7(Clone:2D7), and anti-CD56 PB(Clone:B159) from BD Biosciences (San Jose, California, USA), anti-TF FITC(Clone:VIC7) from American Diagnostica (Stamford, Connecticut, USA), and anti-CD45RO ECD(Clone:UCHL1) from Beckman Coulter (Brea, California, USA), and Live/Dead Fixable Blue Dead Cell Stain Kit with UV excitation from Invitrogen (Grand Island, New York, USA). Samples were acquired on an LSR-II flow cytometer (BD Diagnostic Systems; Franklin Lakes, New Jersey, USA) and data were analyzed using FlowJo software version 9.5.3 (Treestar Inc., Ashland, Oregon, USA).
The following monocyte cell phenotypes were characterized and expressed as proportional percentages:
, tissue factor expression (TF þ ), and expression of tissue migration markers (CCR2 þ , CCR5 þ , CX3CR1 þ ). CD4 þ and CD8 þ T cells phenotypes included the following: CX3CR1 expression, activated phenotype (HLA-DR þ / CD38 þ ), and senescence phenotype (CD57 þ /CD38 þ ). Representative flow cytometry plots are shown in Fig. 1 . Only gated live cells were included in analyses; all cryopreserved samples had more than 75% viability.
The following soluble biomarkers were measured from stored plasma at the Diabetes Research and Training Center Radioimmunoassay Core Laboratory (Washington University School of Medicine, St Louis, Missouri, USA): high-sensitivity C-reactive protein (hsCRP; Kamiya Biomedical Company, Seattle, Washington, USA) and D-dimer (Roche Diagnostics, Indianapolis, Indiana, USA) using immunoturbidometric assays on a Hitachi 917 analyzer; interleukin-6 (IL-6) using electrochemiluminescence assay on Immulite system (Siemens, Erlangen, Germany), and soluble CD14 by ELISA (R&D Systems, Minneapolis, Minnesota, USA). Coronary artery calcium measures CAC was measured from multislice CT scans performed at the baseline and year 2 SUN study visits. Thirty to forty contiguous tomographic slices were obtained at 3-mm intervals beginning 1 cm below the carina and progressing caudally to include the entire coronary tree. All scans were analyzed with a commercially available software package (Neo Imagery Technologies, City of Industry, California, USA). An attenuation threshold of 130 Hounsfield units (HU) and a minimum of three contiguous pixels were utilized to identify a calcific lesion. Each focus was scored using the algorithm developed by Agatston et al. [28] and the total CAC score was determined by summing individual lesion scores from each of four anatomical sites: the left main, left anterior descending, left circumflex, and right coronary arteries [9] . An expert reader, blinded to all clinical and demographic information, read each case for total and per-vessel CAC score.
Statistical methods
We analyzed baseline predictors of progression in CAC over 2 years. Significant CAC progression was defined as incident CAC (score of 0 at baseline and >0 at year 2), or increase in CAC (score >0 at baseline with a positive change at year 2 greater than the measurement error). Previously established methods were applied that defined a threshold for CAC increase beyond measurement error [12, 29] . For this approach, data were square-root transformed and the difference between the CAC values at year 2 and baseline was then calculated ('SQRT method'). A threshold of at least 2.5 mm from the SQRT method corresponded to more than 99th percentile for interscan variability. Given that the majority of the cohort had no detectable CAC, additional methods for studying changes in CAC on a continuous scale could not be applied.
Descriptive statistics of characteristics at baseline and year 2 are presented as medians with interquartile range (IQR) or frequency (number and percentage). Logistic regression models were used to explore the predictors of CAC progression. Univariate models examined associations with baseline characteristics and HIV-related parameters. The frequencies of monocyte and T-cell phenotypes were then studied as predictors of CAC progression (versus no progression) after adjustment for traditional and HIV-related risk factors. Unless otherwise stated, fully adjusted models included the following covariates: age, gender, race/ethnicity, tobacco smoker, diabetes, hepatitis B or C coinfection, treatment with BP or lipid-lowering therapy, baseline CD4 þ cell count, and plasma HIV RNA level (undetectable versus not). Analyses were performed using SAS 9.3 (SAS Institute, Cary, North Carolina, USA); plots were generated with R statistical software 2.10.1 (http://www.R-project. org).
Results
Study population
Of the 691 SUN study participants, baseline or year-2 CAC data were not available for 255 participants, resulting in 436 SUN study participants with paired baseline and 2-year follow-up CAC measurements. Of those participants excluded from the analysis (n ¼ 255), the most common reasons for missing data were as follows: missed CAC measure at either baseline or year 2, but continued in the study (n ¼ 72), withdrew from study (n ¼ 59), moved (n ¼ 36), lost to follow-up (n ¼ 27), and death (n ¼ 11). Compared with any SUN study participant excluded from this analysis, the analysis cohort was slightly older (mean age 42 versus 40 years; P ¼ 0.01), had fewer baseline tobacco smokers (41 versus 48%; P ¼ 0.10), and had a lower prevalence of prior injection drug use (12 versus 17%; P ¼ 0.07), respectively (characteristics for those excluded from analyses presented along with the analysis cohort in Appendix Table  A , http://links.lww.com/QAD/A453).
Baseline characteristics for analysis cohort are presented in Table 1 . Median age was 42 years, the majority were men, over half were non-Hispanic whites, and 41% of participants smoked cigarettes at baseline. Median total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) were within desired ranges for persons without known CVD (67% with TC <200 mg/dl and 73% with LDL-C <130 mg/dl) [30] , and FRSs were consistent with a low CHD risk as estimated by traditional risk factors.
At baseline, 78% of participants were prescribed ART. Of these, 88% had suppressed plasma HIV RNA viral load at baseline and 65% maintained a suppressed HIV RNA viral load at baseline and year 2. The proportion of participants prescribed nonnucleoside reverse transcriptase inhibitor (NNRTI)-based or protease inhibitorbased ART were similar at baseline, and among those prescribed a protease inhibitor atazanavir (35%) and lopinavir (46%) were the most common. Sixty percentage of participants not prescribed ART at baseline started ART after baseline.
Baseline median (IQR) frequencies for monocyte and T-cell phenotypes, and levels of soluble plasma biomarkers, for all SUN study participants are shown in Appendix Table B , http://links.lww.com/QAD/A453. When compared with participants excluded from analyses, the analysis cohort did not differ significantly with respect to the frequency of any of the cellular immunophenotypes studied.
Two-year coronary artery calcium progression Most participants had no detectable CAC at baseline (82%), and similarly at year 2 (75%). Median (IQR) detectable CAC score was 39 (8-136) Agatston units at baseline, and 39 (7-114) Agatston units at year 2. Fifty five participants (12.6%) fulfilled criteria for CAC progression (6.4% with incident CAC and 6.2% with an increase in detectable CAC). The frequency of detectable CAC at baseline and CAC progression over 2 years are presented for subgroups in Table 2 . From unadjusted models, traditional CVD risk factors associated with significant CAC progression included older age, male sex, prescription of BP-lowering therapy, prescription of lipid-lowering therapy, and higher FRS ( Table 3 ). The duration of HIV diagnosis and duration of ART exposure were each associated with greater frequency of CAC progression (Table 3) . Protease inhibitor-based ART was associated with greater CAC progression, but having a detectable HIV viral load (versus <400 copies/ml) was not.
In the fully adjusted model, a higher CD4 þ cell count at baseline (odds ratio, OR 1.12 per 100 cells/ml increase; 95% confidence interval, CI 1.00-1.24; P ¼ 0.04) was, unexpectedly, associated with greater CAC progression. As a result, we further explored the relationship between baseline CD4 þ cell count and duration of HIV diagnosis. Mean (SD) duration of HIV diagnosis at baseline was 5.03 (4.93) years for participants with a CD4 þ cell count less than 500 cells/ml (n ¼ 235), and 6.75 (4.38) years for those with a CD4 þ cell count at least 500 cells/ml (n ¼ 195; P ¼ 0.002 for difference). When duration of HIV diagnosis was added to the fully adjusted model, baseline CD4 þ cell count was no longer predictive of CAC progression (OR 1.08 per 100 cells/ml higher; 95% CI 0.96-1.20; P ¼ 0.21), but duration of HIV diagnosis remained significant (OR 1.08 per year; 95% CI 1.02-1.15; P ¼ 0.008).
Immunologic predictors of coronary artery calcium progression Figure 1 presents flow cytometry plots used to quantify monocyte subsets for representative participants based on presence or absence of CAC progression. After adjusting for traditional and HIV-related risk factors, greater frequencies of CD14 þ /CD16 þ and of CD14 var / CD16 þ monocytes at baseline were independently associated with greater likelihood of CAC progression; the association with CD14 dim /CD16 þ approached significance ( Table 4 column A and Appendix Figure  A , http://links.lww.com/QAD/A453). Associations with monocyte phenotypes appeared to be driven largely by the subset of participants with a significant increase in CAC ( extreme for all the CD16 þ monocyte populations. Finally, adding duration of HIV diagnosis or use of protease inhibitor-based ART to multivariate models did not attenuate associations between monocyte phenotypes and CAC progression (data not shown).
TF expression on monocytes was not associated with CAC progression, nor was expression of the monocyte migration markers CCR2, CCR5, or CX3CR1 in fully adjusted models. Similarly, none of the CD8 þ T-cell phenotypes studied in Table 4 demonstrated independent associations. Finally, none of the inflammatory and coagulation plasma biomarkers were associated with CAC progression.
Discussion
In this cohort of HIV-infected patients with relatively restored immune function and at very low risk for AIDS complications, we describe a novel finding that higher frequencies of CD16 þ monocytes (intermediate and nonclassical phenotypes) predicted greater CAC progression, independent of traditional and HIV-related risk factors. We found no significant associations for other cellular phenotypes, including those reflecting T-cell activation, with CAC progression. These data suggest a potentially important role for monocyte-related cellular activation in coronary atherosclerotic progression among HIV-positive patients, and suggest that the immunologic abnormalities that contribute to risk for non-AIDSdefining comorbidities like CVD among contemporary patients may not predominantly involve T-cell abnormalities that are classically associated with risk for AIDSdefining complications.
The hallmark immunologic abnormalities associated with HIV infection include immune depletion (i.e., low CD4 þ T-cell counts) as well as chronic immune activation, which is most pronounced in untreated disease, but remains present in persons effectively treated with ART [31, 32] . At present, epidemiologic data have been inconsistent with respect to whether CVD risk is associated with immune depletion when measured by absolute CD4 þ cell count [6, [33] [34] [35] [36] . The classic indicator of HIV-related T-cell immune activationthe frequency of CD4 þ and CD8 þ T cells with a CD38 þ / HLA-DR þ phenotype -independently predicts greater risk for AIDS disease progression [15] . In cross-sectional studies, T-cell activation was associated with an increased prevalence of carotid artery atherosclerotic lesions [16, 37] and greater carotid artery stiffness [38] . In contrast, we did not find that CD4 þ or CD8 þ T-cell phenotypes were potential predictors for greater CAC progression, and the potential association with absolute CD4 þ cell count was accounted for by the duration of HIV diagnosis in our analyses.
Coronary artery calcium progression in HIV Baker et al. 837 Odds ratios (ORs) are per log-2 unit higher, which corresponds to a doubling in frequency of given monocyte phenotype, adjusted for age, gender, race/ethnicity, tobacco smoking, diabetes, hepatitis B or C coinfection, treatment for hypertension, treatment for hyperlipidemia, baseline CD4 þ cell count, and undetectable plasma HIV RNA level -except for model restricted to participants with suppressed viral load (<400 copies/ml).
HIV infection, including treated disease, is also characterized by elevations in inflammatory markers and by abnormalities in innate, or nonspecific, immunity, such as a higher prevalence of circulating monocytes that express CD16 þ cell [17, 18, 31, 39, 40] . Although the functional characteristics of intermediate and nonclassical monocyte phenotypes (combined as CD14var/CD16 þ , or CD16 þ , in these analyses) remain controversial, these subsets may be permissive to infection by HIV [41] and exhibit properties that promote atherogenesis [20] [21] [22] [23] . Specifically, the nonclassical phenotype may act as a 'patrolling' subset that has greater affinity for vascular surfaces and preferentially migrate into atherosclerotic lesions [20, 21] . The intermediate monocyte phenotype appears to be functionally more pro-inflammatory, with greater cytokine release after stimulation [20, 22, 23] . Consistent with CD16 þ monocytes being precursors for tissue macrophages, this population has been shown to localize to tissue sites of inflammation and fibrosis, with transendothelial migration facilitated by CX3CL1 [42] . Epidemiologic data from HIV-uninfected participants at risk for CVD (n ¼ 951) also demonstrate that the intermediate monocyte phenotype independently predicts higher risk for subsequent CVD events (i.e. myocardial infarction, stroke, or CVD death) [43] . Our findings are consistent with these data and suggest that nonclassical and intermediate monocyte phenotypes, reflecting greater activation and potential for transendothelial migration, may contribute to excess coronary atherosclerosis in the context of HIV infection. The relative importance of these associations in the context of other known risk factors requires further clarification. While a doubling in the frequency of CD16 þ monocytes conferred risk for CAC progression similar to being 10 years older, this degree of difference in CD16 þ monocytes is substantial (e.g., corresponds to a change from the 25th to 75th percentile).
Recent data support the hypothesis that monocyterelated inflammation has clinical consequences for HIVpositive patients [18, [44] [45] [46] [47] . Soluble CD14 and CD163 levels, both reflecting monocyte activation, have been associated with greater subclinical atherosclerosis among HIV-positive patients and all-cause mortality [45] [46] [47] . Data from the AIDS Clinical Trials Group report further demonstrate that the degree of common carotid intimamedia thickness progression was also positively associated with plasma levels of lipopolysaccharide (LPS), potentially reflecting translocation of microbial products across damaged mucosal surfaces -a mechanism hypothesized to be an important driver of persistent immune activation among HIV-positive patients [45, 48] . Furthermore, Funderburg et al. [18] have shown that LPS levels correlated with the frequency of the intermediate monocyte phenotype (CD14 þ /CD16 þ ) among virally suppressed HIV-positive patients.
An important observation is that the rate of significant CAC progression (12.4% over 2 years) was low among this HIV positive cohort, who were at low risk for CVD (by traditional risk factors) and had high utilization of antiretrovirals that have not been associated with CVD event risk (i.e., tenofovir, atazanavir, NNRTIs) [49, 50] . Specifically, the CAC incident rate was within the expected range for HIV-uninfected participants less than 50 years old reported in the general population cohort MESA (Multi-Ethnic Study of Atherosclerosis) [51] . However, the vast majority of SUN study participants with a detectable CAC score at baseline would still be considered to be at high or very high age-adjusted risk for CHD event (i.e. CAC >75th percentile for age), and would prompt some guidelines to recommend lipidlowering prevention therapy with LDL-C goal of less than 100 or less than 70 mg/dl, respectively [52] . Only 25% of the SUN study participants with detectable CAC at baseline were prescribed lipid-lowering therapy, of which 45% had an LDL-C less than 100 mg/dl. Furthermore, our subgroup analyses demonstrated that the association between CAC progression and the frequency of CD16 þ monocytes was driven by participants who had a significant increase in detectable CAC (versus those with de-novo incident CAC). These data emphasize the need for aggressive risk factor modification among HIV-positive patients with evidence of CHD by noninvasive imaging, and suggest this target population in particular may benefit from adjunct anti-inflammatory treatment strategies. Ultimately, the low rate of CAC progression limited our ability to detect modest associations with potentially important predictors (e.g. TF expression on monocytes and D-dimer levels). However, the lack of association between T-cell phenotypes and CAC progression specifically did not appear to be due to inadequate statistical power, as the OR estimates were very close to one. Additional limitations of our analyses included the lack of an HIV-uninfected comparison population, the inability to adjust for cytomegalovirus serostatus or viremia, the uncertain clinical implications for the degree of CAC change observed, and differences in methodology precluding direct comparison of monocyte subset frequencies to other HIV-uninfected populations. As with any cohort study, causation cannot be established and channeling bias and other unmeasured confounding may be present. The degree to which circulating monocytes reflect pathologic changes in tissue macrophages (e.g. those within atherosclerotic plaques) is also unclear, and our methods did not assess for earlier atherosclerotic lesions such as noncalcified plaque.
In summary, we report the novel finding that higher frequencies of circulating CD16 þ monocytes, reflecting an activated, pro-inflammatory and pro-atherogenic state, predicted greater short-term progression of subclinical coronary atherosclerosis as estimated by CAC. These findings, combined with the lack of associations for activated T cells or immune depletion per se, suggest reducing innate immune activation is a potential CVD prevention strategy for HIV-positive patients.
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